Vitamin D and prostate cancer: a prediagnostic study with stored sera.
Vitamin D and prostate cancer: a prediagnostic study with stored sera.
复制标题
DOI：
--
复制
发表时间：
1993-09
期刊：
影响因子：
--
通讯作者：
Elizabeth H. Corder;Harry A. Guess;Barbara S. Hulka;Gary D. Friedman;Marianne Sadler;Robin T. Vollmer;Bruce Lobaugh;Marc K. Drezner;J. Vogelman;Norman Orentreich
中科院分区：
文献类型：
--
作者：
Elizabeth H. Corder;Harry A. Guess;Barbara S. Hulka;Gary D. Friedman;Marianne Sadler;Robin T. Vollmer;Bruce Lobaugh;Marc K. Drezner;J. Vogelman;Norman Orentreich
这项研究评估了前列腺癌的风险与主要维生素D代谢物25-羟基维生素D（25-D3）和1，25-二羟基维生素D（1，25-D）的血清水平的关系。1964年至1971年期间，从奥克兰和弗朗西斯科的凯撒永久医疗保健计划成员那里收集了25万多份血清样本，并储存起来供将来使用。在1987年12月31日之前诊断为前列腺癌的90名黑人和91名白色男性样本中测量了25-D和1，25-D水平，并在年龄、种族和血清储存日期上单独匹配对照。病例组的平均血清1，25-D水平比对照组低1.81 pg/ml（P = 0.002）。前列腺癌的风险随着1，25-D水平的升高而降低，特别是在25-D水平低的男性中。然而，平均25-D是没有显着差异的情况下和对照组。在血清储存时中位年龄57岁以上的男性中发现了较低的1，25-D与前列腺癌的相关性，但在年轻男性中没有发现，在黑人和白色男性中也相似。在≥ 57岁的男性中，1，25-D是可触及和间变性肿瘤风险的重要预测因子，但对于在手术治疗良性前列腺增生或高分化肿瘤时偶然发现的肿瘤则不是。
This study evaluates the risk of prostate cancer in relation to serum levels of the major vitamin D metabolites, 25-hydroxyvitamin D (25-D3) and 1,25-dihydroxyvitamin D (1,25-D). Between 1964 and 1971, more than 250,000 serum samples were collected from members of the Kaiser Permanente Medical Care Plan in Oakland and San Francisco and stored for future use. Levels of 25-D and 1,25-D were measured in samples from 90 black and 91 white men diagnosed with prostate cancer before December 31, 1987 and controls individually matched on age, race, and day of serum storage. Mean serum 1,25-D was 1.81 pg/ml lower in cases than in matched controls (P = 0.002). Risk of prostate cancer decreased with higher levels of 1,25-D especially in men with low levels of 25-D. However, mean 25-D was not significantly different in cases and controls. The association of lower 1,25-D with prostate cancer was found in men above the median age of 57 years at serum storage but not younger men and was similar in black and white men. In men > or = 57 years of age, 1,25-D was an important predictor of risk for palpable and anaplastic tumors but not for tumors incidentally discovered during surgery to treat the symptoms of benign prostatic hyperplasia or well differentiated tumors.